Instructions to Authors
Read the guidelines below carefully before submitting your abstract. Acknowledgement of the receipt of your submission will be sent to the corresponding author’s e-mail address immediately upon submission. If you do not receive the confirmation e-mail, please do not submit the abstract again, instead please contact the Conference Secretariat at email@example.com for advice.
Invited speakers are not required to submit abstracts for the lectures they are invited to.
- Abstracts must be submitted in English only.
- The text should not exceed 300 words (excluding abstract title & authors).
- Abstracts sent by fax, post or e-mail will not be accepted.
- Tables and graphics can be included in the abstract. These will not add to the word count.
- Straight encore submissions without new data will not be accepted. Encores with additional new data will be considered.
- The text of the abstract should briefly state:
- Objectives (Indicate the purpose of the study or the hypothesis that was tested);
- Methods (Include the setting for the study, the subjects, the diagnosis or intervention and the type of statistical analysis; if references are needed, they should be given in the text);
- Results (Present as clearly as possible the outcome of the study and statistical significance if appropriate);
- Conclusion (Briefly discuss the data and emphasize the significance of the results).
As long as the abstract has not been submitted, it remains in "Draft" status, which means modifications can be made until the abstract submission deadline. A confirmation of receipt will be sent via e-mail upon submission of an abstract.
Presenting authors should register upon submitting their abstract. Registration must be completed at the latest upon confirmation that the abstract has been accepted as an oral or poster presentation.
A. Basic and Translational Science
Antiretroviral Therapy Preclinical
HIV Drug Resistance
Pathogenesis and Immunopathogenesis
Vaccines and Immune Based Therapies
B1. Clinical Science – Antiretroviral Therapy
Antiretroviral Observational Studies
Antiretroviral Randomized Clinical Trials
Pharmacology, Pharmacogenomics and Drug Interactions
B2. Clinical Science – Co-morbidities
HIV-Associated and non HIV-Associated Tumours
Sexually Transmitted Infections
Tuberculosis and Opportunistic Infections
B3. Clinical Science – Hepatitis
B4. Clinical Science – Women, Pregnancy, and Children
C1. Epidemiology/ Public Health
Cascade of Care
Morbidity/Mortality in the Era of cART
Prevalence, Incidence and Dynamics of HIV Epidemics
Prevention of Horizontal Transmission, cART as Prevention
Standard of Care
Clinical Trials of Vaccines
Treatment as Prevention
C3. Social Sciences
Access to and Models of Care
HIV and Marginalised Groups
Social and Behavioural Science
Treatment in Resource-Constrained Settings
Should you have any questions, please contact:
EACS Conference Secretariat
c/o K.I.T. Group GmbH
Association & Conference Management
10709 Berlin, Germany
Phone: +49 30 24603-408